Tsakaneli, A;
Williams, O;
(2021)
Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)-Gene Rearrangements.
Frontiers in Pharmacology
, 12
, Article 741413. 10.3389/fphar.2021.741413.
Preview |
Text
Williams_Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)-Gene Rearrangements_VoR.pdf - Published Version Download (863kB) | Preview |
Abstract
The treatment failure rates of acute leukemia with rearrangements of the Mixed Lineage Leukemia (MLL) gene highlight the need for novel therapeutic approaches. Taking into consideration the limitations of the current therapies and the advantages of novel strategies for drug discovery, drug repurposing offers valuable opportunities to identify treatments and develop therapeutic approaches quickly and effectively for acute leukemia with MLL-rearrangements. These approaches are complimentary to de novo drug discovery and have taken advantage of increased knowledge of the mechanistic basis of MLL-fusion protein complex function as well as refined drug repurposing screens. Despite the vast number of different leukemia associated MLL-rearrangements, the existence of common core oncogenic pathways holds the promise that many such therapies will be broadly applicable to MLL-rearranged leukemia as a whole.
| Type: | Article |
|---|---|
| Title: | Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)-Gene Rearrangements |
| Location: | Switzerland |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3389/fphar.2021.741413 |
| Publisher version: | https://doi.org/10.3389/fphar.2021.741413 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | ALL, AML, MLL-rearrangements, drug repurposing, leukemia |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10136323 |
Archive Staff Only
 |
View Item |
